Document Type

Conference Proceeding

Publication Date


Publication Title

Annals of Surgical Oncology


INTRODUCTION: Immediate breast reconstruction after a mastectomy was reported in 43.3% of female patients in 2014; and has been associated with improved quality of life and adherence to adjuvant therapies. While there are many studies regarding immediate breast reconstruction in women, little has been reported about reconstruction rates and outcomes in male breast cancer. The purpose of this study is to examine the trends and outcomes of performing Immediate Breast Reconstruction (IBR) in male breast cancer (MBC) patients following a mastectomy. METHODS: The National Cancer Database (NCDB) registry from 2004 to 2014 was used to identify non-metastatic MBC patients who had a mastectomy with or without an IBR. Patients’ demographics, readmission, and long-term overall mortality (OM) were compared between IBR and no-IBR patients. Univariate, multivariate, and propensity score weighted analyses were used to compare study groups and outcomes. RESULTS: 370 (3.35%) IBR and 10,677 (96.65%) no-IBR patients were identified. Median follow-up was 59.63 months. Compared to no-IBR patients, IBR patients were more likely to be younger (Mean:52, SD:11.7 vs. Mean:65.8, SD:12.8), be Hispanic, live in a metropolitan county, and have private insurance, less comorbidities and higher income (P< 0.05). Rates of IBR increased significantly from 1.56% in 2004 to 4.15% in 2014 (P< 0.05). IBR types were 130 (35%) tissue-based, 96 (26%) implant-based, 42 (11%) combined tissue/implant, and 102 (28%) were non specified. IBR was not associated with 30-Day readmission or 90-Day mortality. In the adjusted propensity score weighted analysis, IBR was not associated with OM for stage I (HR:0.45, P=0.23), stage II (HR:0.95, P=0.92), or stage III (HR:1.48, P=34) cancer cases. CONCLUSIONS: Our data suggest that IBR in MBC patients has been increasing over the years, with the tissue-based IBR as the most common type. There was no association between IBR and 30-Day readmission rates or overall mortality when compared to MBC patients who did not receive an IBR.




Suppl 2

First Page


Last Page


Included in

Surgery Commons